Compare American States Water Company (AWR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American States Water Company vs Recursion Pharmaceuticals Inc — how do they compare? American States Water Company trades at $87.57 (market cap $3.47B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: American States Water Company is the larger of the two by market cap, and American States Water Company pays a 2.49% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AWR | RXRX | |
|---|---|---|
Market Cap | $3.47B | $1.81B |
Sector | Utilities | Health |
52-Week High | $89.28 | $6.79 |
52-Week Low | $70.10 | $2.84 |
Enterprise Value | $4.37B | $1.33B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American States Water (AWR) trades at $87.83, up 1.46% today, with strong technical momentum as moving averages signal bullish alignment. The company maintains robust fundamentals with 20.52% net income margin and consistent dividend growth, recently increasing its quarterly payout by 8.2%. Recent Q2 2026 earnings beat expectations at $1.09 per share, driven by water rate increases and operational gains across business segments.
Outlook remains stable with revenue growth and dividend reliability, though valuation multiples appear elevated versus utilities peers. Key risks include regulatory dependence on rate approvals and competitive pressures. Analyst sentiment is mixed with 20% buy ratings amid concerns about current price levels relative to earnings potential.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
